Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05082519 · ClinicalTrials.gov registry record · Phase 2
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
A Phase 2 study of Obesity and B-cell Acute Lymphoblastic Leukemia, sponsored by Etan Orgel.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 240
- Enrollment target
- 20
- Study locations
NCT05082519: Recruiting Phase 2 study of Obesity and B-cell Acute Lymphoblastic Leukemia, sponsored by Etan Orgel.
NCT05082519 is a Phase 2 study of Obesity and B-cell Acute Lymphoblastic Leukemia that is actively recruiting participants, run by Etan Orgel. The registered enrollment target is 240 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (71% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05082519, a Phase 2 study of Obesity and B-cell Acute Lymphoblastic Leukemia, is actively recruiting participants, sponsored by Etan Orgel.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 240 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL. Chemotherapy during the first month causes large gains in body fat in most people, even those who start chemotherapy at a healthy weight. This study is being done to find out if caloric restriction achieved by a personalized nutritional menu and exercise plan during routine chemotherapy can make the patient's ALL more sensitive to chemotherapy and also reduce the amount of body fat gained during treatment. The goals of this study are to help make chemotherapy more effective in treating the patient's leukemia as demonstrated by fewer patients with leukemia minimal residual disease (MRD) while also trying to reduce the amount of body fat that chemotherapy causes the patient to gain in the first month.
Primary Outcome
To compare the rate of MRD \>=0.01% at end of induction between experimental arm and control arm
Conditions Studied
Interventions
- BEHAVIORAL IDEAL2 Intervention
Study Locations (20)
California
- Children's Hospital Los Angeles - Los Angeles
- Children's Hospital Orange County - Orange
- UCSF School of Medicine - San Francisco
Texas
- University of Texas, Southwestern - Dallas
- Cook Children's Medical Center - Fort Worth
- Baylor Texas Children's Hospital - Houston
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
- Nationwide Children's Hospital - Columbus
Colorado
- Colorado Children's Hospital - Denver
Georgia
- Children's Healthcare of Atlanta at Egleston - Atlanta
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
Maryland
- Johns Hopkins / Sydney Kimmel Cancer Center - Baltimore
Michigan
- C.S. Mott University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2022-03-12 |
| Est. Completion | 2031-10-15 |
| Phase | Phase 2 |
What NCT05082519 shows while recruiting
NCT05082519 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (71% lower).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 1 intervention - of which IDEAL2 Intervention is the first listed.
NCT05082519 names 20 study sites across 15 states, led by California, Texas, Ohio.
Frequently Asked Questions
What is clinical trial NCT05082519 about?
NCT05082519 is a clinical study titled "Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL". This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL. Chemotherapy during the first month causes large gains in body fat in most people, even t...
What is the current status of trial NCT05082519?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2022-03-12. Estimated completion is 2031-10-15.
What conditions does trial NCT05082519 study?
This clinical trial studies the following conditions: Obesity, B-cell Acute Lymphoblastic Leukemia.
What interventions are being tested in trial NCT05082519?
The interventions under investigation include: IDEAL2 Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT05082519?
This trial is sponsored by Etan Orgel, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05082519 being conducted?
This trial has 20 study locations across California, Colorado, Georgia, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05082519's enrollment target sits among peer trials
240 270th of 1053 higher than 779 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI